Biochip Langdao (Tianjin)Medical Technology Limited

1.Product Overview

[Product Name] : Myoglobin (Myo)

[Package Specification] :30 tests/kit;60 tests/kit

[Applicable Device] : CLite-160i

[Specimen Type] : Serum or plasma

[Storage] : 2-8℃

[Product validity] : 12 months

[Detection method] : magnetic particle chemiluminescence method

2.technique principle

 Double antibody sandwich method was used in the kit. The detection principle is: the sample to be tested, R1 reagent, R2 reagent and M reagent are mixed for incubation, and the fluorescein (FITC) labeled MYO antibody 1 in R1 reagent and the alkaline phosphatase (ALP) labeled MYO antibody 2 in R2 reagent are combined with the MYO antigen molecules in the sample to form an immune complex. The immune complex is further captured by anti-FITC antibodies coupled to the surface of the magnetic particle and adsorbed to the surface of the magnetic particle. After washing, the unbound material was removed and the luminescent substrate was added, ALP catalyzed the luminescence of the substrate, and the relative luminescence intensity (RLU) was determined.

3.Clinical significance

Myoglobin (Myo), with a molecular weight of 17.8kD, is composed of a polypeptide chain and a heme cofactor. Myo is present in human skeletal muscle and myocardial cells and carries oxygen for cellular respiration.In the early stage of acute myocardial infarction (AMI), Myo has a small molecular weight and can be rapidly released from the damaged cells. The concentration of Myo in serum rises rapidly after 1 ~ 3h and reaches the peak at 6 ~ 7h. Within 12h, Myo in almost all patients with AMI increases, and the increase is greater than that of myocardial enzymes. Therefore can be used as early diagnostic markers of AMI.Because Myo is also present in skeletal muscle and is only cleared from the kidney, Myo is elevated in patients with acute muscle injury, acute or chronic renal failure, severe congestive heart failure, prolonged shock and myopathy caused by various reasons, intramuscular injection, strenuous exercise, and ingestion of certain toxins and drugs.Therefore, the determination of serum Myo level must be combined with other aspects of patient evaluation to assist in the diagnosis of AMI. In patients with acute symptoms, Myo within 4 h level does not rise, the low possibility of AMI. Since the blood Myo after AMI soon cleared from kidney, the onset of l8 within 30 h ~ can fully recover to normal level.Therefore, the measurement of Myo is helpful to observe whether there is reinfarction or infarct expansion during the course of AMI. Myo was frequently increased, suggesting that the original myocardial infarction was still continuing. In addition, serum Myo levels are also increased in neuromuscular diseases such as muscular dystrophy, amyotrophy and polymyositis. Serum Myo is elevated in patients undergoing cardiac surgery, which can be used as an objective index to judge the degree of myocardial injury and healing.

4.Product features and indicators

High sensitivity: the detection limit is not higher than 20ng/mL;

Wide linear range: [21,3000] (ng/mL) within the scope of sample without hook phenomenon;

Good correlation: correlation R > 0.95 with ROCHE reagent;

Good stability: the calibration cycle can be up to 14 days, the reagent can be stored at 4℃ for 1 year;

Fast results: only 18 minutes to get results.